DCY636 / Novartis - LARVOL DELTA

A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P1 | N=63 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Atopic Dermatitis • Dermatitis • Dermatology • Immunology